Start Your Risk-Free Subscription

Login

The Daily Biopharmaceutical News Source

Advanced Search

BioWorld-International-2005-12-28

Scientists Follow TRAIL Of Resistant Ovarian Cancer

Cerep Gets Mixed Results From Anticancer Drug Phase I/II Trial

By James Etheridge

Wednesday, December 28, 2005

PARIS - Cerep SA reported encouraging, but mixed, results from a proof-of-concept Phase I/II trial of a cancer drug developed by its subsidiary, Cerenis, which is being tested in refractory or relapsing acute myeloid leukemia (AML). (BioWorld International)

»

Login or register to post comments
Read more

Novartis Interest Could Scuttle Crucell's Bid For Berna Biotech

By Cormac Sheridan

Wednesday, December 28, 2005

No Abstract

»

Login or register to post comments
Read more

Scientists Follow TRAIL Of Resistant Ovarian Cancer

By Sharon Kingman

Wednesday, December 28, 2005

No Abstract

»

Login or register to post comments
Read more

NovaThera, Texas Heart Institute Form Agreement

By Nuala Moran

Wednesday, December 28, 2005

No Abstract

»

Login or register to post comments
Read more

Foundation Setting Up Plans For Nanomedicine Use In EU

By Nuala Moran

Wednesday, December 28, 2005

No Abstract

»

Login or register to post comments
Read more

Other News To Note

Wednesday, December 28, 2005

No Abstract

»

Login or register to post comments
Read more

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA

Part of Thompson Media Group LLC
Thompson.com | Sheshunoff.com | ASPratt.com | AHCMedia.com | BioWorld.com | CMEweb.com | ThePerformanceInstitute.org | ASMIweb.com

Editorial Guidelines

For Site License Discounts, please contact Customer Service at (800) 477-6307 or customerservice@bioworld.com.